HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplements Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Campagna, F. Articles by Arca, M. Search for Related Content PubMed PubMed Citation Articles by Campagna, F. Articles by Arca, M. Related Collections Molecular Diagnostics and Genetics

Congenital Analbuminemia attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene

¹ Department of Clinical and Applied Medical Therapy,² Department of Clinical Sciences, and³ IV Division of Internal Medicine, Department of Experimental Medicine and Pathology, University of Rome, La Sapienza, Italy;

^aaddress correspondence to this author at: Dipartimento di Clinica e Terapia Medica Applicata, Università di Roma "La Sapienza", Policlinico Umberto I, Viale del Policlinico, 155, 00161 Rome, Italy; fax 39-06-4440290, e-mail marcelloarca@libero.it

The first 300 words of the full text of this article appear below.

Congenital analbuminemia is a rare autosomal recessive disorder characterized by the absence or very low concentrations of serum albumin (HSA) (1). The disorder is conventionally defined as an HSA <1 g/L (as determined by immunoassay) associated with normal liver function and absence of protein loss (2). The incidence of congenital analbuminemia is estimated to be <1 in 1 million births, without sex or race predilection. To date, 39 cases of congenital analbuminemia have been reported, 16 of which were diagnosed in children (3). Despite multiple functions of HSA (4), its absence is a relatively tolerable condition. Except for associated hyperlipidemia, minor edema, and mild fatigability, analbuminemic individuals suffer few adverse symptoms (3)(5)(6). Such relative mildness of symptoms is attributed to a compensatory increase in hepatic biosynthesis of other plasma proteins (7)(8).

Congenital analbuminemia is attributable to defects in the gene coding for HSA. The HSA gene is located on chromosome 4 and is split into 15 exons by 14 intervening introns (9). The identification of multiple mutations that cause analbuminemia clearly indicates that it is a genetically heterogeneous disorder. Six of these mutations introduced stop codons (10)(11)(12)(13), and 2 caused splicing defects and determined a premature termination of the translation (14)(15). All were found to be present in the homozygous state. In the present study we characterized another case of congenital analbuminemia caused by 2 newly identified mutations in an Italian family.

The proband was a 29-year-old Italian man with an HSA of 10–12 mg/L as determined by immunoassay. His medical history has been reported elsewhere (16)(17). The proband’s relatives had HSA concentrations in . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				L. Dolcini, G. Caridi, M. Dagnino, A. Sala, S. Gokce, S. Sokucu, M. Campagnoli, M. Galliano, and L. Minchiotti Analbuminemia Produced by a Novel Splicing Mutation Clin. Chem., August 1, 2007; 53(8): 1549 - 1552. [Abstract] [Full Text] [PDF]